UCB SA
Stock
Stock
ISIN: BE0003739530
Ticker: UCB
BE0003739530
UCB
Price
Price
CHART BY
Historical dividends and forecast
UCB SA has so far distributed $1.451 in 2024. The next dividend will be paid on 30.04.2025
$1.273
CHART BY
Frequently asked questions
What is UCB SA's market capitalization?
The market capitalization of UCB SA is $36.93B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is UCB SA's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for UCB SA is 147.63. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for UCB SA?
UCB SA's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.319. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for UCB SA's stock?
Currently, 18 analysts cover UCB SA's stock, with a consensus target price of $214.14. Analyst ratings provide insights into the stock's expected performance.
What is UCB SA's revenue over the trailing twelve months?
Over the trailing twelve months, UCB SA reported a revenue of $5.69B.
What is the EBITDA for UCB SA?
UCB SA's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.25B. EBITDA measures the company's overall financial performance.
What is the free cash flow of UCB SA?
UCB SA has a free cash flow of $517.48M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does UCB SA have, and what sector and industry does it belong to?
UCB SA employs approximately 9,083 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of UCB SA's shares?
The free float of UCB SA is 116.68M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $36.93B
- EPS (TTM)
- $1.319
- Free Float
- 116.68M
- P/E ratio (TTM)
- 147.63
- Revenue (TTM)
- $5.69B
- EBITDA (TTM)
- $1.25B
- Free Cashflow (TTM)
- $517.48M
Pricing
- 1D span
- $186.23$196.11
- 52W span
- $84.81$203.75
Analyst Ratings
The price target is $214.14 and the stock is covered by 18 analysts.
Buy
12
Hold
5
Sell
1
Information
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
- Employees
- 9,083
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- BE0003739530
- Primary Ticker
- UCB